Peter Lang

13PUBLICATIONS

136CO-AUTHORS

Haematological tumoursHaematologyCancer therapy (excl. chemotherapy and radiation therapy)Sensor technology (incl. chemical aspects)Molecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|May 29, 2026

A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma.

|Mar 27, 2026

Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT.

Simone Cesaro, Chiara Garonzi, Gloria Tridello

|Jan 11, 2025

Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.

Tim Flaadt, Jonas Rehm, Thorsten Simon

|Dec 03, 2024

Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.

Maximilian Stich, Vladimir Gonçalves Magalhães, Friederike Bürger

|Feb 07, 2024

Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression.

Barbara Meissner, Peter Lang, Peter Bader

|Oct 14, 2023

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.

Tim Flaadt, Martin Ebinger, Malin Schreiber

Pageof 3

Frequent Collaborators

Roland Meisel

Tim Flaadt

Thorsten Simon

Johannes H Schulte

Brigitte Strahm

Holger N Lode

Hedwig E Deubzer

Ingo Müller

Bernd Gruhn

Peter Bader

Frequent Collaborators

Roland Meisel

Tim Flaadt

Thorsten Simon

Johannes H Schulte